Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

Research output: Contribution to journalArticlepeer-review

Standard

Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations. / Talip, Zeynep; Borgna, Francesca; Müller, Cristina; Ulrich, Jiri; Duchemin, Charlotte; Fernandes Pinto Ramos, João Pedro; Stora, Thierry; Köster, Ulli; Nedjadi, Youcef ; Maratovich Gadelshin, Vadim; Fedosseev, Valentin N.; Juget, Frederic; Bailat, Claude J.; Fankhauser, Adelheid; Wilkins, Shane; Lambert, Laura; Marsh, Bruce A; Fedorov, Dmitry; Chevallay, Eric; Fernier, Pascal; Schibli, Roger; van der Meulen, Nicholas P.

In: Frontiers in Medicine, Vol. 8, 643175, 22.04.2021, p. 1-11.

Research output: Contribution to journalArticlepeer-review

Harvard

Talip, Z, Borgna, F, Müller, C, Ulrich, J, Duchemin, C, Fernandes Pinto Ramos, JP, Stora, T, Köster, U, Nedjadi, Y, Maratovich Gadelshin, V, Fedosseev, VN, Juget, F, Bailat, CJ, Fankhauser, A, Wilkins, S, Lambert, L, Marsh, BA, Fedorov, D, Chevallay, E, Fernier, P, Schibli, R & van der Meulen, NP 2021, 'Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations', Frontiers in Medicine, vol. 8, 643175, pp. 1-11. https://doi.org/10.3389/fmed.2021.643175

APA

Talip, Z., Borgna, F., Müller, C., Ulrich, J., Duchemin, C., Fernandes Pinto Ramos, J. P., Stora, T., Köster, U., Nedjadi, Y., Maratovich Gadelshin, V., Fedosseev, V. N., Juget, F., Bailat, C. J., Fankhauser, A., Wilkins, S., Lambert, L., Marsh, B. A., Fedorov, D., Chevallay, E., ... van der Meulen, N. P. (2021). Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations. Frontiers in Medicine, 8, 1-11. [643175]. https://doi.org/10.3389/fmed.2021.643175

Vancouver

Talip Z, Borgna F, Müller C, Ulrich J, Duchemin C, Fernandes Pinto Ramos JP et al. Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations. Frontiers in Medicine. 2021 Apr 22;8:1-11. 643175. https://doi.org/10.3389/fmed.2021.643175

Author

Talip, Zeynep ; Borgna, Francesca ; Müller, Cristina ; Ulrich, Jiri ; Duchemin, Charlotte ; Fernandes Pinto Ramos, João Pedro ; Stora, Thierry ; Köster, Ulli ; Nedjadi, Youcef ; Maratovich Gadelshin, Vadim ; Fedosseev, Valentin N. ; Juget, Frederic ; Bailat, Claude J. ; Fankhauser, Adelheid ; Wilkins, Shane ; Lambert, Laura ; Marsh, Bruce A ; Fedorov, Dmitry ; Chevallay, Eric ; Fernier, Pascal ; Schibli, Roger ; van der Meulen, Nicholas P. / Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations. In: Frontiers in Medicine. 2021 ; Vol. 8. pp. 1-11.

Bibtex - Download

@article{aab62eb68b2d4d6e81b3b23ab28352a3,
title = "Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations",
abstract = "The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.",
keywords = "Er-169, Electromagnetic isotope separation, Lanthanide-separation, Activity standardization, In vitro studies, Laser resonance ionization",
author = "Zeynep Talip and Francesca Borgna and Cristina M{\"u}ller and Jiri Ulrich and Charlotte Duchemin and {Fernandes Pinto Ramos}, {Jo{\~a}o Pedro} and Thierry Stora and Ulli K{\"o}ster and Youcef Nedjadi and {Maratovich Gadelshin}, Vadim and Fedosseev, {Valentin N.} and Frederic Juget and Bailat, {Claude J.} and Adelheid Fankhauser and Shane Wilkins and Laura Lambert and Marsh, {Bruce A} and Dmitry Fedorov and Eric Chevallay and Pascal Fernier and Roger Schibli and {van der Meulen}, {Nicholas P.}",
note = "Score=10",
year = "2021",
month = apr,
day = "22",
doi = "10.3389/fmed.2021.643175",
language = "English",
volume = "8",
pages = "1--11",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media SA",

}

RIS - Download

TY - JOUR

T1 - Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

AU - Talip, Zeynep

AU - Borgna, Francesca

AU - Müller, Cristina

AU - Ulrich, Jiri

AU - Duchemin, Charlotte

AU - Fernandes Pinto Ramos, João Pedro

AU - Stora, Thierry

AU - Köster, Ulli

AU - Nedjadi, Youcef

AU - Maratovich Gadelshin, Vadim

AU - Fedosseev, Valentin N.

AU - Juget, Frederic

AU - Bailat, Claude J.

AU - Fankhauser, Adelheid

AU - Wilkins, Shane

AU - Lambert, Laura

AU - Marsh, Bruce A

AU - Fedorov, Dmitry

AU - Chevallay, Eric

AU - Fernier, Pascal

AU - Schibli, Roger

AU - van der Meulen, Nicholas P.

N1 - Score=10

PY - 2021/4/22

Y1 - 2021/4/22

N2 - The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.

AB - The β−-particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168Er2O3. This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169Er from 168Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169Er. The quality of the 169Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169Er-PSMA-617, to show the potential of 169Er to reduce tumor cell viability.

KW - Er-169

KW - Electromagnetic isotope separation

KW - Lanthanide-separation

KW - Activity standardization

KW - In vitro studies

KW - Laser resonance ionization

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/45021037

U2 - 10.3389/fmed.2021.643175

DO - 10.3389/fmed.2021.643175

M3 - Article

VL - 8

SP - 1

EP - 11

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

M1 - 643175

ER -

ID: 7176228